ATE203277T1 - Verfahren zur bestimmung der wirksamkeit einer testsubstanz - Google Patents

Verfahren zur bestimmung der wirksamkeit einer testsubstanz

Info

Publication number
ATE203277T1
ATE203277T1 AT94112272T AT94112272T ATE203277T1 AT E203277 T1 ATE203277 T1 AT E203277T1 AT 94112272 T AT94112272 T AT 94112272T AT 94112272 T AT94112272 T AT 94112272T AT E203277 T1 ATE203277 T1 AT E203277T1
Authority
AT
Austria
Prior art keywords
coagulation factor
factor xii
blood coagulation
blood
tested substance
Prior art date
Application number
AT94112272T
Other languages
English (en)
Inventor
Katsumi Nishikawa
Nobuyuki Ishibashi
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Application granted granted Critical
Publication of ATE203277T1 publication Critical patent/ATE203277T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2337/00N-linked chromogens for determinations of peptidases and proteinases
    • C12Q2337/10Anilides
    • C12Q2337/12Para-Nitroanilides p-NA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • G01N2333/96441Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96458Factor XII (3.4.21.38)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT94112272T 1993-08-06 1994-08-05 Verfahren zur bestimmung der wirksamkeit einer testsubstanz ATE203277T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21517793A JP3213831B2 (ja) 1993-08-06 1993-08-06 被検物質の活性測定方法

Publications (1)

Publication Number Publication Date
ATE203277T1 true ATE203277T1 (de) 2001-08-15

Family

ID=16667948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94112272T ATE203277T1 (de) 1993-08-06 1994-08-05 Verfahren zur bestimmung der wirksamkeit einer testsubstanz

Country Status (8)

Country Link
US (1) US5599683A (de)
EP (1) EP0637633B1 (de)
JP (1) JP3213831B2 (de)
KR (1) KR100270161B1 (de)
CN (1) CN1080763C (de)
AT (1) ATE203277T1 (de)
DE (1) DE69427723T2 (de)
ES (1) ES2159535T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1084995A (ja) * 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第xii因子活性化法
US6632678B2 (en) 2001-01-03 2003-10-14 Sienco, Inc. Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
US20030143444A1 (en) * 2002-01-31 2003-07-31 Qin Liu Fuel cell with fuel droplet fuel supply
US20060024745A1 (en) * 2002-12-20 2006-02-02 Pritchard David J Variants of factor XllA
RU2504771C2 (ru) * 2011-06-29 2014-01-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) Способ отбора анальгетических средств

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB697351A (en) * 1951-01-16 1953-09-23 Masuichi Takino Improved process for the manufacture of nerve sedatives
JPS53101515A (en) * 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS5777697A (en) * 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS5835117A (ja) * 1981-08-25 1983-03-01 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質nsh
ATE17262T1 (de) * 1981-11-02 1986-01-15 Pentapharm Ag Verfahren zur quantitativen bestimmung von blutgerinnungsfaktor xii in humanplasma.
DE3504405A1 (de) * 1985-02-08 1986-08-14 Boehringer Mannheim Gmbh, 6800 Mannheim Bestimmung von prokallikrein
JPS63185398A (ja) * 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) * 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
JP2651674B2 (ja) * 1987-07-23 1997-09-10 日本臓器製薬 株式会社 新規生理活性物質及びその製造方法
US4985254A (en) * 1987-11-06 1991-01-15 Nippon Zoki Pharmaceutical Co., Ltd. Method of treating ischemic diseases
EP0341209B1 (de) * 1988-04-30 1993-09-15 Nippon Zoki Pharmaceutical Co. Ltd. Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon
JP2539665B2 (ja) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 神経疾患治療剤
CA2082643A1 (en) * 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof

Also Published As

Publication number Publication date
EP0637633B1 (de) 2001-07-18
EP0637633A2 (de) 1995-02-08
CN1110409A (zh) 1995-10-18
DE69427723T2 (de) 2002-05-08
EP0637633A3 (de) 1998-01-07
US5599683A (en) 1997-02-04
KR100270161B1 (ko) 2000-10-16
DE69427723D1 (de) 2001-08-23
KR950006461A (ko) 1995-03-21
ES2159535T3 (es) 2001-10-16
JPH0751097A (ja) 1995-02-28
JP3213831B2 (ja) 2001-10-02
CN1080763C (zh) 2002-03-13

Similar Documents

Publication Publication Date Title
DE69018910D1 (de) Verfahren zur Bestimmung des endogenen Thrombinpotentials von Plasma und Blut und Reagenziensatz zur Verwendung in besagtem Verfahren.
DE3788762D1 (de) Verfahren zur Bestimmung von physiologisch wirksamen Substanzen.
CA2252983A1 (en) Method for determining the anticoagulatory potential of a sample
DE59409698D1 (de) Verfahren zur Bestimmung der Thrombozytenaggregation
US20210071229A1 (en) Fibrinogen test
ES2152531T3 (es) Prueba para determinar el riesgo de trombosis.
ATE203277T1 (de) Verfahren zur bestimmung der wirksamkeit einer testsubstanz
EP1367135A1 (de) Verbessertes Verfahren zur Beurteilung der Thrombinbildung in Blutplasma
US4918001A (en) Method for the determination of protease inhibitors
DE60009879T2 (de) Bestimmung von biologisch aktiven formen von proteolytischen enzymen
ATE136367T1 (de) Verfahren zur bestimmung von hirudin und synthetischen trhombininhibitoren
ATE194659T1 (de) Verfahren zur prüfung der wirksamkeit einer testsubstanz
ATA99992A (de) Verfahren zur bestimmung von fibrinogen
ATE191278T1 (de) Tetrahydroxychinon als eine aktivatorkomponente für den aktivierten partiellen thromboplastinzeit-test der blutgerinnung und als anzeiger von blutgerinnungsstörungen
Nishikawa et al. Method for measuring production activity of test substance towards FXIIA
ATE208504T1 (de) Komplex-gebundene hemmstoffe aktivierbarer stoffwechselenzyme als molekulare marker zur diagnostik und therapieüberwachung
CZ88093A3 (en) Application of prothrombin fragments
ATE213274T1 (de) Verfahren zur beurteilung der aktivität von arzneistoffen
Hertfelder et al. Evaluation of normal values for fibrin monomers, thrombin-antithrombin III-complex, t-PA-and PAI-activities in human plasma
Kirchhof et al. Early detection of DIC by screening methods
Holtkötter et al. Determination of fibrin monomers in pathological plasma samples

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee